Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide or methotrexate plus subcutaneous TNF-alpha blockers in rheumatoid arthritis
ISRCTN62900439Phase 4Completed
- Sponsor
- St John of God University Hospital
- Start
- May 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of leflunomide, methotrexate, etanercept and adalimumab in rheumatoid arthritis (RA) (2 arms), sponsored by St John of God University Hospital. Primary endpoints: Disease activity over 2 years and Remission and low disease activity rates. Started May 2005; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ISRCTN62900439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN62900439.